Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and Thymalfasin in metastatic small cell lung cancer
NCT02542137Phase 2Withdrawn
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Sep 2015
- Primary completion
- Dec 2018
- Modality
- Peptides
01
Overview
Phase 2, open-label, single-arm trial of thymosin alpha 1 in small cell lung cancer (SCLC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Proportion of patients with an abscopal response. Planned start Sep 2015; status: withdrawn.
02
Drugs
thymosin alpha 1
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02542137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02542137.